Essential hypertension
Therapeutic area
Vascular Medicine
Rare disease
Yes
- Definition
- Hypertension that presents without an identifiable cause.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Essential hypertension
- Therapeutic area
- Vascular Medicine
- essential hypertension
- idiopathic hypertension
- primary hypertension
- Severity
- Mild
- Cardiology
- Vascular Medicine
- MONDO ID
- MONDO:0001134
- Parent condition
- MONDO:0005044
Related records
Broader conditions (7)
- Arterial disorder
- Cardiovascular disorder
- Disease
- Disease by body system or component
- Human disease
- Hypertensive disorder
- Vascular disorder
Narrower conditions (3)
- Benign essential hypertension
- Essential hypertension, genetic
- Malignant essential hypertension
Trials (464)
- A Bioequivalence Study of L04TD3 Compared to Administration of L04RD1 in Healthy Volunteers
- A Cardiosleep Research Program on Obstructive Sleep Apnea, Blood Pressure Control and Maladaptive Myocardial Remodeling
- A Clinical Study to Evaluate Efficacy and Safety of Fimasartan/Hydrochlorothiazide Combination-therapy
- A Clinical Trial to Compare and Evaluate the Pharmacokinetic Characteristics and the Safety of Fimasartan in Hepatic Impairment Patients and Healthy Volunteers
- A Clinical Trial to Evaluate the Blood Pressure Control of Telmisartan or Losartan in Essential Hypertensive Patients With Metabolic Syndrome
- A Clinical Trial to Evaluate the Effect of Fimarsartan on Pharmacodynamics, Pharmacokinetics, and the Safety of Warfarin in Healthy Male Volunteers
- A Dose Selection Trial of CKD-330 in Patients With Essential Hypertension
- A Long Term Safety Study to Test the Combination of Aliskiren/ Amlodipine / Hydrochlorothiazide in Participants With Essential Hypertension
- A Long-term (12 Months) Safety, Tolerability and Efficacy Study of LCZ696 in Patients With Essential Hypertension
- A Long-term Study of the Safety of MK-0954A in Patients With Essential Hypertension (MK-0954A-351)
- A Multicenter Study to Evaluate the ROX Coupler in Subjects With Hypertension
- A Multicenter, Randomized, Double-Blind Phase 3 Trial of KDF1901 in Patients With Essential Hypertension
- A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in China
- A National Multicentre Study to Assess the Efficacy of the Fixed Combination of Valsartan and Amlodipine in Hypertensive Patients Not Controlled by Monotherapy
- A Phase 2 Dose Selection Trial of Candesartan Cilexetil and Amlodipine Besylate to Treat Essential Hypertension
- A Phase II Clinical Study of QR12000 Compound Tablets in Patients With Moderate to Severe Essential Hypertension
- A Phase III Clinical Study of Valsartan Oral Solution for the Treatment of Hypertension in Children and Adolescents
- A Phase III Clinical Trial Evaluating the Efficacy and Safety of Valsartan/Levamlodipine (SYH9056) Tablets In Hypertensive Patients
- A Phase III Long-term Study of TAK-536TCH in Participants With Essential Hypertension
- A Phase III Study to Efficacy and Safety of DWC202405/DWC202313 and DWC202314 in Patients With Hypertension
Approved drugs (1)
Drugs in development (57)
- ACT-280778 Phase 2
- Alcohol Phase 2
- Aliskiren Phase 3
- Allopurinol Phase 2
- Amlodipine Phase 3
- Amlodipine besylate Phase 3
- Aprocitentan Phase 2
- Arginine Phase 2
- Atenolol Phase 3
- Atorvastatin Phase 1
- Azilsartan Phase 3
- Azilsartan medoxomil Phase 3
- Beraprost sodium Early phase 1
- Bexagliflozin Phase 2
- Butane Phase 1
- Candesartan Phase 3
- Candesartan cilexetil Phase 3
- Captopril Phase 3
- Carvedilol Phase 3
- Chlorthalidone Phase 3
Other linked drugs (5)
- Colchicine
- Iloprost
- Mecamylamine
- Seractide acetate
- Tilarginine